A double‐blind, placebo‐controlled study of house dust mite immunotherapy in Chinese asthmatic patients

Abstract

One year treatment with Alutard SQ house dust mite immunotherapy significantly reduced symptoms and medication use in asthmatic subjects. This was associated with a greater subjective improvement in asthma control.

Chinese Guideline on allergen immunotherapy for allergic rhinitis

“…All these studies demonstrated that the AIT treated group had a significant decline in the medication score compared with the placebo group (54,55,134,234).…”

“…Patients with new sensitization have been shown to have higher atopy scores and medication scores for both rhinitis and asthma than patients without new sensitization, after 5 years of AIT treatment (50)(51)(52)55,56). Interestingly, one study has demonstrated that the risk of development of new sensitization was 3-fold higher in the control group than in the SIT-aq (SIT with aqueous extracts) group and 4-fold higher in the control group than in the SIT-ad (SIT with adsorbed extracts) group (57).…”

“…The efficacy of AIT in asthma is measured using symptom scores, medication scores, as well as lung function test (55,134,(233)(234)(235). The symptom and medication scores are frequently used as primary endpoints in AIT trials.…”

“…The nocturnal asthma symptoms are scored from 0 to 4 points according to the frequency of nocturnal and early morning awakening by asthma. The total asthma symptom score (TASS) is the sum of daytime and nocturnal asthma symptoms scores, and generally been evaluated monthly in most studies (54,55,134,234,235).…”

“…The parameters included FEV 1 % predicted, PEF rate in the morning and night, PEF% predicted value as well as brochoprovocation tests (54,55,(233)(234)(235)237). However, within-group analysis in some studies failed to demonstrate significant differences between AIT and control groups (233,234,236).…”